Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3576-3583

  Shipley, W U ^a   Winter, K A ^a   Kaufman, D S ^a   Lee, W R ^a   Heney, N M ^a   Tester, W R ^a   Donnelly, B J ^a   Venner, P M ^a   Perez, C A ^a   Murray, K J ^a   Doggett, R S ^a   True, L D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; FOLLOW UP; HUMAN; IRRADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE; TRANSURETHRAL RESECTION; TUMOR LOCALIZATION;

EID: 0031763392     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3576     Document Type: Article

References (26)

1. Dunst J, Sauer R, Schrott KM, et al: An organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994
2. Housset M, Maulard C, Chretien YC, et al: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993
3. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993
4. Tester W, Porter A, Heaney J, et al: Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer. J Clin Oncol 14:119-126, 1996
5. Kaufman DS, Shipley WU, Griffin PP, et al: Selective preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993
6. Kachnic LA, Kaufman DS, Griffin PP, et al: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15:1022-1029, 1997
7. Coppin CML, Gospodarowicz MK, James K, et al: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901-2907, 1996
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Asoc 53:457-481, 1958
9. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities. J Am Stat Assoc 88:400-409, 1993
10. Agresti A: Analysis of Ordinal Categorical Data. New York, NY, Wiley, 1984
11. Cox DR: Regression methods and life tables. J R Stat Soc 34:187-220, 1972
12. Jenkins BJ, Blandy JP, Caulfield MJ, et al: Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder cancer. Br J Urol 62:343-346, 1988
13. Shearer RJ, Chilvers CE, Bloom HJG, et al: Adjuvant chemotherapy in T3 carcinoma of the bladder. Br J Urol 62:558-564, 1988
14. Gospodarowicz MK, Hawkins MV, Rawling GA, et al: Radical radiotherapy tor muscle invasive transitonal cell carcinoma of the bladder: Failure anlaysis. J Urol 142:1448-1454, 1989
15. Pollack A, Zagars G, Swanson D: Muscle-invasive bladder cancer treated with external-beam radiotherapy: Prognostic factors, Int J Radiat Oncol Biol Phys 30:267-77, 1994
16. DeNeve W, Lybeert ML, Goor C, et al: Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiat Oncol 36:183-188, 1995
17. Bloom HJG, Hendry WF, Wallace DM, et al: Treatment of T3 bladder cancer: Controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54:136-151, 1982
18. Sell A, Jakobsen A, Nerstrom B: Treatment of advanced bladder cancer category T2,T3,T4a. Scand J Urol Nephrol 138:193-201, 1991 (suppl)
19. Wallace DMA, Raghavan D, Kelley K, et al: Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67:608-612, 1991
20. Martinez-Pineiro JA, Martin MG, Arocena NF, et al: Neoadjuvant cisplatin chemotherapy before radical cystecotmy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 153:964-973, 1995
21. Hall RR: Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer: First analysis of MRC/EORTC intercontinental trial. Proc Am Soc Clin Oncol 15:244, 1996 (abstr)
22. Malmstrom PU, Rintala E, Wahlquist R, et al: Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. J Urol 155:1903-1906, 1996
23. Logothetis C, Swanson D, Amato R, et al: Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241 -1245, 1996
24. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliuin. J Urol 135:461-469, 1988
25. Tannock I, Gospodarowicz M, Connolly J, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
26. Javle M, Raghavan D: Systemic therapy for invasive bladder cancer. Cancer Contr 3:501-506, 1996